High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer

Daniel L Suzman, Emmanuel S Antonarakis, Daniel L Suzman, Emmanuel S Antonarakis

No abstract available

Keywords: Biochemical recurrence; Hedgehog pathway; Itraconazole; Prostate cancer.

Conflict of interest statement

Conflicts of Interest: DS reports no conflicts of interest related to this work. ESA reports no conflicts of interest related to this work.

Figures

Figure 1

The patient achieved a 50% reduction in PSA after administration of high-dose itraconazole. Testosterone levels remained in the non-castrate range, while DHEA levels paradoxically increased. Clinically and biochemically, the patient demonstrated no evidence of hypocortisolism or adrenal insufficiency. In fact, itraconazole treatment resulted in hypoaldosteronism and an elevation of ACTH levels. Hyperbilirubinemia developed after 5 months of itraconazole treatment, but resolved after drug discontinuation.